Thus, systems biology and artificial intelligence approaches can contribute to exploring unanswered questions and this may guide the development of ALK TKIs and the identification of the optimal treatment sequence in ALK+ NSCLC patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.